Research Article
The Effect of Residence Time of No-tunneled Hemodialysis Catheters on Infection and Thrombosis Outcome. Identification of CVC’s Time Cut-off
Luciano De Paola*, Mariantonia Panzino, Laura Saturno, Maria Antonietta Mascaro, Marco Vatrano, Federica De Paola, Citraro Maria Lucia, Bova Francesca, D’Onofrio Giuseppina and Giovanni Ruotolo
Published: 04 March, 2024 | Volume 8 - Issue 1 | Pages: 023-031
Introduction: Permanent vascular access (arteriovenous fistula (AVF), arteriovenous graft (AVG)) is susceptible to acute events that reduce patency. The temporary central venous catheter (CVC) constitutes bridging therapy for primary vascular access dysfunction. The impact of “residence time” on the rate of dysfunction/thrombosis or infection remains to be explored.
AIM: 1) To evaluate the impact of CVC residence time on outcomes (infection or Thrombosis/dysfunction) in consecutive temporary CVCs adjusted for the insertion site (upper site vs. lower site).
2) To establish a cut-off resident time.
Patients and methods: Seventeen prevalent hemodialysis patients with three consecutive CVCs are followed up prospectively in an observational study for a period equivalent to the permanence of the CVCs. The data is recorded at the beginning of the CVC time. The diagnosis of catheter-related bloodstream infection and thrombosis/dysfunction is made following the K-Doqi 2019 guidelines.
Statistical analysis: Seventeen hemodialysis patients (51 CVCs) were included. The ‘CVC resident time’ of each individual patient ((i.e. βcoefficient (log-transformed)*AUC)) was determined using LMM and then inserted into multivariate Cox models to assess infection and dysfunction/thrombosis outcomes (Joint Models). The AUC was calculated at various baseline levels of CVC time (10th……50th percentile). The cut-off point for thrombosis in CVC time corresponds to the mean of the CVC time at the 30th percentile of all CVCs.
Results: The CVC time is different for CVC’s site insertion and sequence. From the analysis of multivariate joint models, CVC resident time appears not to be significant for infection, but heterogenicity for the insertion site (ref3-4=upper site) is significant for the outcome of thrombosis/dysfunction. From the study of survival analysis, the free survival from outcomes by CVC site insertion appears to be significant for thrombosis/dysfunction. The average time of CVCs’ calculation at the 30th percentile is 14 days (cut-off).
Conclusion: No tunneled hemodialysis Catheter (NTHC) residence time is considered not to be a risk factor for infection, but it represents a risk factor for lower access thrombosis. After the cut-off time of 14 days, the advantage of the higher NTHCs is lost.
Read Full Article HTML
DOI: 10.29328/journal.jcn.1001122
Cite this Article
Read Full Article PDF
Keywords:
No tunneled hemodialysis; Catheter (NTHC); Hemodialysis; Infection; Thrombosis
References
- Malas MB, Canner JK, Hicks CW, Arhuidese IJ, Zarkowsky DS, Qazi U, Schneider EB, Black JH 3rd, Segev DL, Freischlag JA. Trends in incident hemodialysis access and mortality. JAMA Surg. 2015 May;150(5):441-8. doi: 10.1001/jamasurg.2014.3484. PMID: 25738981.
- Ko GJ, Rhee CM, Obi Y, Chang TI, Soohoo M, Kim TW, Kovesdy CP, Streja E, Kalantar-Zadeh K. Vascular access placement and mortality in elderly incident hemodialysis patients. Nephrol Dial Transplant. 2020 Mar 1;35(3):503-511. doi: 10.1093/ndt/gfy254. PMID: 30107612; PMCID: PMC7057539.
- Napalkov P, Felici DM, Chu LK, Jacobs JR, Begelman SM. Incidence of catheter-related complications in patients with central venous or hemodialysis catheters: a health care claims database analysis. BMC Cardiovasc Disord. 2013 Oct 16;13:86. doi: 10.1186/1471-2261-13-86. PMID: 24131509; PMCID: PMC4015481.
- Dugué AE, Levesque SP, Fischer MO, Souweine B, Mira JP, Megarbane B, Daubin C, du Cheyron D, Parienti JJ; Cathedia Study Group. Vascular access sites for acute renal replacement in intensive care units. Clin J Am Soc Nephrol. 2012 Jan;7(1):70-7. doi: 10.2215/CJN.06570711. Epub 2011 Nov 10. PMID: 22076877; PMCID: PMC3265351.
- O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011 May;52(9):e162-93. doi: 10.1093/cid/cir257. Epub 2011 Apr 1. PMID: 21460264; PMCID: PMC3106269.
- Weijmer MC, Vervloet MG, ter Wee PM. Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. Nephrol Dial Transplant. 2004 Mar;19(3):670-7. doi: 10.1093/ndt/gfg581. PMID: 14767025.
- Klouche K, Amigues L, Deleuze S, Beraud JJ, Canaud B. Complications, effects on dialysis dose, and survival of tunneled femoral dialysis catheters in acute renal failure. Am J Kidney Dis. 2007 Jan;49(1):99-108. doi: 10.1053/j.ajkd.2006.09.014. PMID: 17185150.
- Lawson JH, Niklason LE, Roy-Chaudhury P. Challenges and novel therapies for vascular access in haemodialysis. Nat Rev Nephrol. 2020 Oct;16(10):586-602. doi: 10.1038/s41581-020-0333-2. Epub 2020 Aug 24. PMID: 32839580; PMCID: PMC8108319.
- Clark EG, Barsuk JH. Temporary hemodialysis catheters: recent advances. Kidney Int. 2014 Nov;86(5):888-95. doi: 10.1038/ki.2014.162. Epub 2014 May 7. PMID: 24805107; PMCID: PMC4220490.
- Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS, Abreo K, Allon M, Asif A, Astor BC, Glickman MH, Graham J, Moist LM, Rajan DK, Roberts C, Vachharajani TJ, Valentini RP; National Kidney Foundation. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020 Apr;75(4 Suppl 2):S1-S164. doi: 10.1053/j.ajkd.2019.12.001. Epub 2020 Mar 12. Erratum in: Am J Kidney Dis. 2021 Apr;77(4):551. PMID: 32778223.
- Al-Jaishi AA, Lok CE, Garg AX, Zhang JC, Moist LM. Vascular access creation before hemodialysis initiation and use: a population-based cohort study. Clin J Am Soc Nephrol. 2015 Mar 6;10(3):418-27. doi: 10.2215/CJN.06220614. Epub 2015 Jan 7. PMID: 25568219; PMCID: PMC4348683.
- Parienti JJ, Thirion M, Mégarbane B, Souweine B, Ouchikhe A, Polito A, Forel JM, Marqué S, Misset B, Airapetian N, Daurel C, Mira JP, Ramakers M, du Cheyron D, Le Coutour X, Daubin C, Charbonneau P; Members of the Cathedia Study Group. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA. 2008 May 28;299(20):2413-22. doi: 10.1001/jama.299.20.2413. PMID: 18505951.
- KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006 May;47(5 Suppl 3):S11-145. doi: 10.1053/j.ajkd.2006.03.010. Erratum in: Am J Kidney Dis. 2006 Sep;48(3):518. PMID: 16678659.
- Merrer J, De Jonghe B, Golliot F, Lefrant JY, Raffy B, Barre E, Rigaud JP, Casciani D, Misset B, Bosquet C, Outin H, Brun-Buisson C, Nitenberg G; French Catheter Study Group in Intensive Care. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA. 2001 Aug 8;286(6):700-7. doi: 10.1001/jama.286.6.700. PMID: 11495620.
- Choi SR, Lee YK, Cho AJ, Park HC, Han CH, Choi MJ, Koo JR, Yoon JW, Noh JW. Malnutrition, inflammation, progression of vascular calcification and survival: Inter-relationships in hemodialysis patients. PLoS One. 2019 May 2;14(5):e0216415. doi: 10.1371/journal.pone.0216415. PMID: 31048884; PMCID: PMC6497382.
- Trottier SJ, Veremakis C, O'Brien J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. Crit Care Med. 1995 Jan;23(1):52-9. doi: 10.1097/00003246-199501000-00011. PMID: 8001386.
Figures: